title: [Experimental study of combination of ciprofloxacin and oxytocin on formation of biofilms by opportunistic bacteria].
abstract: OBJECTIVE
  To study in vitro and in vivo effect of oxytocin and ciprofloxacin combination on formation of biofilms by agents of surgical infections.
  
  
  METHODS
  Microorganisms of different species isolated by conventional methods from patients with purulent soft tissue infections were used in experiments. Ciprofloxacin manufactured by "Dr. Reddys" (India) and oxytocin manufactured by "Gedeon Richter" (Hungary) were used. For in vitro experiments one-half of minimal inhibitory concentrations of drugs were used. Oxytocin-placebo ("Gedeon Richter", Hungary) was used for control tests. Formation of biofilms was assessed using method proposed by G. O'Toole (2000). For in vivo experiments septic wounds in 1st phase of wound process were modeled according to method proposed by E.M. Danilova (1992). Wounds were infected with Staphylococcus aureus strain 104, which has strong ability to form biofilms. Efficacy of treatment was assessed on signs of inflammatory process and microscopy of touch smears for detection of bacterial biofilms.
  
  
  RESULTS
  In experiments in vivo addition of oxytocin to nutrient medium resulted in suppression of biofilm formation by studied microorganisms. Obtained data were confirmed by in vivo experiments which demonstrated higher efficacy of local application of ciprofloxacin and oxytocin combination for treatment of septic wounds compared to separate use of ciprofloxacin or oxytocin.
  
  
  CONCLUSIONS
  Studies performed in vitro and in vivo showed efficacy of oxytocin and ciprofloxacin combination, which is determined not only by enhancement of antimicrobial effect of the drug against pathogen but also by suppression of biofilm formation in the wound during infection.
authors.forename: Iu I
authors.initials: IuI
authors.lastname: Skorobogatykh
authors.forename: N B
authors.initials: NB
authors.lastname: Perunova
authors.forename: P P
authors.initials: PP
authors.lastname: Kurlaev
authors.forename: O V
authors.initials: OV
authors.lastname: Bukharin
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018441:Biofilms / Q000187:drug effects*; D002939:Ciprofloxacin / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D010121:Oxytocin / Q000494:pharmacology; D051381:Rats; D018461:Soft Tissue Infections / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D013492:Suppuration / Q000188:drug therapy / Q000382:microbiology
chemical_list: D000890:Anti-Infective Agents; D010121:Oxytocin; D002939:Ciprofloxacin